Eagle Pharmaceuticals (EGRX) Tops Q2 EPS by 4c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Eagle Pharmaceuticals (EGRX) PT Raised to $120 at Piper Jaffray
August 12, 2015 8:28 AM EDTPiper Jaffray analyst David Amsellem reiterated an Overweight rating and lifted his price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $120.00 (from $119.00) following the company's Q2 update.
commented, "This morning, Eagle reported net results per share of ($0.53) on revenues of $6M. Management provided... More
